Amneal Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 616.98 million compared to USD 609.76 million a year ago. Net loss was USD 98.65 million compared to USD 4.33 million a year ago. Basic loss per share from continuing operations was USD 0.4 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.4 compared to USD 0.03 a year ago.

For the full year, the company reported sales was USD 2,393.61 million compared to USD 2,212.3 million a year ago. Net loss was USD 83.99 million compared to USD 129.99 million a year ago. Basic loss per share from continuing operations was USD 0.48 compared to USD 0.86 a year ago. Diluted loss per share from continuing operations was USD 0.48 compared to USD 0.86 a year ago.